Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP/GLP-1 Co-Activity in Overweight Type 2 Diabetes
NCT03526289Completed
- Sponsor
- Gentofte Hospital
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of glucose-dependent insulinotropic polypeptide[1-42] in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gentofte Hospital. Primary endpoint: Difference in food intake. Started Nov 2017; status: completed.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03526289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526289.